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domized, controlled investigations with a sufficient number of
patients are needed. However, the general public and the medical
community should be reassured by our study that the severity of
the problem is probably much less than initially thought.
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Risk of Neutropenia With Clopidogrel
Dr. Berger et al. presented a cogent comparison of ticlopidine and
clopidogrel after intracoronary artery stent placement (1). How-
ever, they present misleading information regarding the side effects
of clopidogrel. They state, “Clopidogrel does not cause neutrope-
nia . . . ” (1). The authors use the CAPRIE trial as a supporting
reference. In the CAPRIE trial “ . . . the numbers for low neutro-
phil counts were ten (0.10%) and 16 (0.17%) (clopidogrel and
aspirin groups, respectively). Among these latter cases, the neu-
trophil count fell below 0.45 3 10ˆ9/L for five (0.05%) and four
(0.04%) patients in the clopidogrel and aspirin groups, respective-
ly., . . . In CAPRIE, there was no excess neutropenia in the
clopidogrel group (2).” Hence, more appropriately, the authors
should have stated that the risk of neutropenia is less than with
ticlopidine but essentially equivalent to aspirin.
It is important for cardiologists to remember that clopidogrel
can be associated with neutropenia, albeit very infrequently.
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REPLY
We appreciate Dr. Dieter’s interest in our article and the oppor-
tunity to respond to his letter. Patients in CAPRIE were inten-
sively monitored for neutropenia, and severe neutropenia (,450
per microliter) was observed in six patients, four of whom were
receiving clopidogrel (three women, one man, all of whom were
Caucasian). Although these patients did develop neutropenia while
receiving clopidogrel, we disagree with Dr. Dieter’s conclusion that
clopidogrel “caused” the neutropenia in these patients. One patient
was receiving chemotherapy for a malignancy when the neutrope-
nia occurred. Two patients developed only transient neutropenia,
which did not resume after clopidogrel was reinitiated, and they
continued to receive clopidogrel for the duration of the study. We
should mention that a fifth clopidogrel patient was described in the
CAPRIE manuscript as having developed neutropenia but was
found to have aplastic anemia and was, therefore, not considered
by the Food and Drug Administration to have developed “neutro-
penia.” This fifth clopidogrel patient does not appear in the
labeling for clopidogrel. (Similarly, two additional aspirin patients
were described in the CAPRIE manuscript as having developed
neutropenia; one had actually developed acute myelogenous leu-
kemia, and one was found to have been neutropenic at study
entry.)
Despite the “association” between clopidogrel and neutropenia
in these four patients, we are no more convinced that clopidogrel
caused their neutropenia than we are convinced that aspirin caused
the neutropenia in the two patients in the aspirin group. It is
important to distinguish between the frequency of “background”
Table 1.
Mitral Regurgitation Aortic Regurgitation
Age Men Women Men Women Men Women
26–39 0.186 0.142 0 0 0 0
40–49 0.302 0.361 0.003 0.009 0.017 0.007
50–59 0.442 0.383 0.016 0.01 0.042 0.021
60–69 0.07 0.115 0.024 0.023 0.127 0.068
70–83 0 0 0.112 0 0.144 0.169
.83 0 0 0.112 0 0.144 0.169
Expected prevalence 0.010 0.010 0.033 0.018
Total expected prevalence 0.010 0.021
Observed prevalence 0.013 0.066
Prevalence ratio 1.34 3.13
95% confidence limits 0.41–4.35 0.99–9.85
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